“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: Actinogen Medical
Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific and selective 11beta-HSD1 inhibitor designed to treat cognitive impairment (CI), which occurs in chronic neurodegenerative and neuropsychiatric diseases.
Actinogen Medical — 4 videos in collection
Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific and selective 11β-HSD1 inhibitor designed to treat cognitive impairment (CI), which occurs in chronic neurodegenerative and neuropsychiatric diseases.
In this interview, chief executive officer Dr Steven Gourlay describes the commercial opportunities and next development steps for Xanamem in Alzheimer’s disease (AD) and for CI in relation to major depressive disorder. He also discusses promising indications of therapeutic activity from a recent analysis of patients in its XanADu study in mild AD with confirmed disease through blood biomarker testing.
Get access to the very latest content matched to your personal investment style.
